Individualization of anti-VEGF treatment protocols can reduce treatment burden on patients with age-related macular degeneration ... hemorrhages or fluid seen on OCT images.

(HealthDay)—For about 20 percent of patients with neovascular age-related macular degeneration ... vascular endothelial growth factor (VEGF) treatment, according to a study published online Oct ...

Faricimab demonstrated short-term improvements in visual and anatomical outcomes for nAMD patients switching from other anti-VEGF therapies ... neovascular age-related macular degeneration ...

Shares of Ocular Therapeutix (NASDAQ:OCUL) spiked on Wednesday after the company said its Phase 3 registrational trial SOL-R ...

Marco Govel/Stocksy United The number of people with age-related macular degeneration (AMD ... regulators have approved injections of anti-VEGF medications to treat AMD. Researchers looked ...

People with a condition called wet age-related macular degeneration (AMD ... Most of these medicines are called anti-VEGF therapies because they block a substance in the eye called vascular ...

A small pilot study previously showed that UBX1325 achieved sustained improvement in visual acuity in patients with DME or neovascular age-related macular degeneration. While anti-VEGF agents have ...

Anti–vascular endothelial growth factor (VEGF) medications have been a mainstay of treatment for wet age-related macular degeneration (wet AMD) for 20 years — and for good reason. The ...

There's no cure, but treatment for age-related macular degeneration (AMD ... the abnormal vessels that cause wet AMD. Vascular endothelial growth factor (VEGF) is the main protein that causes ...

Diagnosing age-related macular degeneration. BrightFocus Foundation. The eye exam for macular degeneration. American Academy of Ophthalmology. Anti-VEGF treatments. National Eye Institute.